MINNEAPOLIS, Dec. 21,
2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Kim
Kelderman, current Chief Operating Officer, and Chief
Executive Officer effective February 1,
2024, will present at the 42nd Annual J.P. Morgan
Healthcare Conference on Wednesday, January
10, 2024, at 9:00 a.m. PST. A
live webcast of the presentation can be accessed via the IR
Calendar page of Bio-Techne's Investor Relations website at
https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) is a leading
developer and manufacturer of high-quality purified proteins and
reagent solutions - notably cytokines and growth factors,
antibodies, immunoassays, biologically active small molecule
compounds, tissue culture reagents, T-Cell activation and gene
editing technologies. Bio-Techne's product portfolio also includes
protein analysis solutions, sold under the ProteinSimple brand
name, offering researchers efficient and streamlined options for
automated Western blot and multiplexed ELISA workflow. These
reagent and protein analysis solutions are sold to biomedical
researchers as well as clinical research laboratories and
constitute the Protein Sciences Segment. Bio-Techne also develops
and manufactures diagnostic products including FDA-regulated
controls, calibrators, blood gas and clinical chemistry controls
and custom assay development on dedicated clinical instruments.
Bio-Techne's genomic tools include advanced tissue-based in
situ hybridization assays (ISH) for research and clinical use,
sold under the ACD brand as well as a portfolio of clinical
molecular diagnostic oncology assays, including the
ExoDx® Prostate test for prostate cancer diagnosis.
These diagnostic and genomic products comprise Bio-Techne's
Diagnostics and Genomics Segment. Bio-Techne products are integral
components of scientific investigations into biological processes
and molecular diagnostics, revealing the nature, diagnosis,
etiology and progression of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide.
Contact:
|
David Clair, Vice
President, Investor Relations & Corporate
Development
|
|
david.clair@bio-techne.com
|
|
612-656-4416
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302019228.html
SOURCE Bio-Techne Corporation